Form 8-K IMMUCELL CORP /DE/ For: Jan 28
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications ...
Model output · Signal date 2026-11-06
Immucell Corp /De/ (ICCC) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
-31.0%
Spearman, 357 dates
Market Cap
$90M
small-cap · #10 of 17 peers
Summary
Immucell Corp /De/ (ICCC) stock forecast summary
Our AI scores Immucell Corp /De/ every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Immucell Corp /De/ is a small-cap company with a market capitalization of $90M. It ranks number 10 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast.
For ICCC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -31.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -15.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ICCC included.
Price
ICCC price chart and AI forecast
Cross-section · 2026-11-06
How ICCC ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Immucell Corp /De/ (ICCC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | ICCC | Rank |
|---|---|---|
| Market Cap | $90M | 10/17 |
| P/E Ratio | 497.63x | – |
| P/B Ratio | 2.88x | 5/12 |
| EPS | $0.02 | – |
| Book Value/Share | $3.45 | – |
| Revenue/Share | $3.38 | – |
| FCF/Share | $0.46 | – |
Profitability & Margins
| Metric | ICCC | Rank |
|---|---|---|
| ROE | 2.5% | 3/10 |
| ROA | 1.7% | 3/12 |
| ROIC | 9.2% | 3/12 |
| Gross Margin | 40.3% | 7/9 |
| Operating Margin | 12.6% | 4/14 |
| Net Margin | 2.6% | 4/11 |
| EBT Margin | 2.8% | 4/14 |
| Tax Rate | 7.8% | – |
Financial Health
| Metric | ICCC | Rank |
|---|---|---|
| Current Ratio | 4.75x | 4/16 |
| Quick Ratio | 2.71x | 4/10 |
| D/E Ratio | 0.49x | 8/12 |
| Financial Leverage | 1.49x | 8/12 |
| Interest Coverage | 20.4x | 2/15 |
| Working Capital | $17M | 9/16 |
Cash Flow
| Metric | ICCC | Rank |
|---|---|---|
| Operating Cash Flow | $6M | 4/16 |
| Free Cash Flow | $4M | 3/10 |
| Capital Spending | -$2M | 4/10 |
| OCF Growth YoY | 132.6% | 1/5 |
| FCF Growth YoY | 138.9% | – |
| FCF/Sales | 13.7% | 3/10 |
| CapEx/Sales | 5.5% | 4/10 |
Operational Efficiency
| Metric | ICCC | Rank |
|---|---|---|
| Asset Turnover | 0.66x | 3/12 |
| Receivables Turnover | 10.6x | 1/11 |
| Inventory Turnover | 2.0x | 10/10 |
| Fixed Assets Turnover | 1.5x | 7/12 |
| Days Sales Outstanding | 34 days | 11/11 |
| Days Inventory | 181 days | 1/10 |
| Payables Period | 56 days | 6/10 |
| Cash Conversion Cycle | 159 days | 1/8 |
Income Statement
| Metric | ICCC | Rank |
|---|---|---|
| Total Revenue | $31M | 8/12 |
| Operating Income | $4M | 3/15 |
| Net Income | $790K | 3/12 |
| R&D Expense | $2M | 14/16 |
| SG&A Expense | $10M | 9/12 |
| Cost of Goods Sold | $18M | 7/10 |
Dividend & Shareholder Information
| Metric | ICCC | Rank |
|---|---|---|
| Shares Outstanding | 9M | – |
| Net Income Growth | -40.5% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $21M | 45.2% of assets |
| Cash & Short-term Investments | $9M | 19.0% of assets |
| Accounts Receivable | $3M | 6.2% of assets |
| Inventory | $9M | 19.5% of assets |
| Total Liabilities | $15M | 32.7% of assets |
| Short-term Debt | $2M | 3.5% of assets |
Quarterly Financial Reports
ICCC quarterly financials and insider trading
Industry Peers · In Vitro & In Vivo Diagnostic Substances
Immucell Corp /De/ (ICCC) industry peers
Companies classified under the same SEC industry code as Immucell Corp /De/ (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ICCC Immucell Corp /De/ | $90M | |
| IDXX Idexx Laboratories Inc /De | $53.26B | |
| LNTH Lantheus Holdings, Inc. | $6.57B | |
| NEOG Neogen Corp | $2.57B | |
| CLDX Celldex Therapeutics, Inc. | $2.35B | |
| NTLA Intellia Therapeutics, Inc. | $1.59B | |
| QDEL Quidelortho Corp | $734M | |
| ACHV Achieve Life Sciences, Inc. | $692M | |
| MYGN Myriad Genetics Inc | $566M | |
| TKNO Alpha Teknova, Inc. | $482M | |
| IMDX Insight Molecular Diagnostics Inc. | $81M | |
| AWHL Aspira Women's Health Inc. | $9M | |
| BMRA Biomerica Inc | $7M | |
| CDIO Cardio Diagnostics Holdings, Inc. | $5M | |
| TRIB Trinity Biotech Plc | $5M | |
| QCLS Q/C Technologies, Inc. | $3M | |
| VNRX Volitionrx Ltd | $3M |
Where ICCC sits on the market map
Life Sciences · In Vitro & In Vivo Diagnostic Substances
News
Immucell Corp /De/ (ICCC) stock news
Robert C Bruce's Net Worth
Robert C Bruce does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include LIHUA INTERNATIONAL INC., ...
FAQ
Immucell Corp /De/ (ICCC) stock forecast FAQ
What is the Immucell Corp /De/ (ICCC) stock forecast?
Our AI scores Immucell Corp /De/ every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Immucell Corp /De/ stock predictions?
For ICCC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -31.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -15.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Immucell Corp /De/ forecasts updated?
Immucell Corp /De/ forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Immucell Corp /De/'s industry peers?
17 issuers in our coverage, ICCC included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.